Share the post "Jagsonpal Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Down 21.58 %, QoQ Down 7.93 %"
Highlights
- Sales over the Year and quarter: The company’s sales declined by -21.58 % over the year, decrease in net sales/revenue by -7.93 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -2.73 %, Marginal decrease of -1.19% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for Jagsonpal Pharmaceuticals Limited. Profit dropped by -36.66 % Year to Year, Jagsonpal Pharmaceuticals Limited’s profitability dropped by -10.45 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -38.79 % Year to Year. EPS decreased by -11.49 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 55.451 Cr | Rs. 47.234 Cr | Rs. 43.486 Cr | -7.93 % | -21.58 % |
| Expenses | Rs. 50.01 Cr | Rs. 43.83 Cr | Rs. 40.81 Cr | -6.89 % | -18.4 % |
| Operating Profit | Rs. 5.44 Cr | Rs. 3.4 Cr | Rs. 2.68 Cr | -21.18 % | -50.74 % |
| OPM % | 9.81 % | 7.2 % | 6.16 % | -1.04 % | -3.65 % |
| Other Income | Rs. 2.56 Cr | Rs. 2.52 Cr | Rs. 2.49 Cr | -1.19 % | -2.73 % |
| Interest | Rs. 0.2 Cr | Rs. 0.23 Cr | Rs. 0.22 Cr | -4.35 % | + 10 % |
| Depreciation | Rs. 0.48 Cr | Rs. 0.41 Cr | Rs. 0.4 Cr | -2.44 % | -16.67 % |
| Profit before tax | Rs. 7.32 Cr | Rs. 5.28 Cr | Rs. 4.55 Cr | -13.83 % | -37.84 % |
| Tax % | 23.48 % | 24.93 % | 21.76 % | -3.17 % | -1.72 % |
| Net Profit | Rs. 5.6 Cr | Rs. 3.96 Cr | Rs. 3.55 Cr | -10.35 % | -36.61 % |
| EPS in Rs | Rs. 2.14 | Rs. 1.48 | Rs. 1.31 | -11.49 % | -38.79 % |
Today, we’re looking at Jagsonpal Pharmaceuticals Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -21.58 %. However, it did see a marginal slip of -7.93 % from the previous quarter. Expenses decreased slightly by -6.89 % quarter-on-quarter, aligning with the annual decline of -18.4 %. Operating profit, while down -50.74 % compared to last year, faced a quarter-on-quarter dip of -21.18 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -3.65 %, but a shrinkage of -1.04 % sequentially. Other income fell by -1.19 % compared to the last quarter, despite an annual decline of -2.73 %. Interest expenses dropped significantly by -4.35 % from the previous quarter, yet the year-over-year increase remains at a moderate 10 %. Depreciation costs fell by -2.44 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -16.67 %. Profit before tax declined annually by -37.84 % but saw a reduction from the preceding quarter by -13.83 %.
Tax expenses as a percentage of profits decreased slightly by -1.72 % compared to last year, with a more notable quarter-on-quarter decrease of -3.17 %. Net profit fell by -36.61 % year-on-year but witnessed a -10.35 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -38.79 % but a quarterly fall of -11.49 %. In summary, Jagsonpal Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 55.451 Cr | Rs. 47.234 Cr | Rs. 43.486 Cr | -7.93 % | -21.58 % |
| Expenses | Rs. 50.01 Cr | Rs. 43.83 Cr | Rs. 40.81 Cr | -6.89 % | -18.4 % |
| Operating Profit | Rs. 5.44 Cr | Rs. 3.4 Cr | Rs. 2.68 Cr | -21.18 % | -50.74 % |
| Net Profit | Rs. 5.6 Cr | Rs. 3.96 Cr | Rs. 3.55 Cr | -10.35 % | -36.61 % |
| EPS in Rs | Rs. 2.14 | Rs. 1.48 | Rs. 1.31 | -11.49 % | -38.79 % |
In reviewing Jagsonpal Pharmaceuticals Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -21.58 % year-on-year, although there was a slight dip of -7.93 % from the previous quarter. Expenses decreased by -18.4 % compared to the previous year, with a decrease of -6.89 % quarter-on-quarter. Operating Profit dropped by -50.74 % annually, and saw a -21.18 % decrease from the last quarter.
Net Profit showed yearly decrease of -36.61 %, and experienced a -10.35 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -38.79 % annually, however dipped by -11.49 % compared to the last quarter. In essence, while Jagsonpal Pharmaceuticals Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
